Burden of Type 1 and Type 2 Diabetes and High Fasting Plasma Glucose in Europe, 1990-2019: a Comprehensive Analysis from the Global Burden of Disease Study 2019

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Dec 28

PMID 38152139

Authors

Dong Liang

Xiuli Cai

Qing Guan

Yangjiang Ou

Xiaoxin Zheng

Xiuquan Lin

Affiliations

Soon will be listed here.

Abstract

Introduction: With population aging rampant globally, Europe faces unique challenges and achievements in chronic disease prevention. Despite this, comprehensive studies examining the diabetes burden remain absent. We investigated the burden of type 1 and type 2 diabetes, alongside high fasting plasma glucose (HFPG), in Europe from 1990-2019, to provide evidence for global diabetes strategies.

Methods: Disease burden estimates due to type 1 and type 2 diabetes and HFPG were extracted from the GBD 2019 across Eastern, Central, and Western Europe. We analyzed trends from 1990 to 2019 by Joinpoint regression, examined correlations between diabetes burden and Socio-demographic indices (SDI), healthcare access quality (HAQ), and prevalence using linear regression models. The Population Attributable Fraction (PAF) was used to described diabetes risks.

Results: In Europe, diabetes accounted for 596 age-standardized disability-adjusted life years (DALYs) per 100,000 people in 2019, lower than globally. The disease burden from type 1 and type 2 diabetes was markedly higher in males and escalated with increasing age. Most DALYs were due to type 2 diabetes, showing regional inconsistency, highest in Central Europe. From 1990-2019, age-standardized DALYs attributable to type 2 diabetes rose faster in Eastern and Central Europe, slower in Western Europe. HFPG led to 2794 crude DALYs per 100,000 people in 2019. Type 1 and type 2 diabetes burdens correlated positively with diabetes prevalence and negatively with SDI and HAQ. High BMI (PAF 60.1%) and dietary risks (PAF 34.6%) were significant risk factors.

Conclusion: Europe's diabetes burden was lower than the global average, but substantial from type 2 diabetes, reflecting regional heterogeneity. Altered DALYs composition suggested increased YLDs. Addressing the heavy burden of high fasting plasma glucose and the increasing burden of both types diabetes necessitate region-specific interventions to reduce type 2 diabetes risk, improve healthcare systems, and offer cost-effective care.

Citing Articles

Global disease burden of breast cancer attributable to high fasting plasma glucose: a comprehensive analysis from the global burden of disease study.

Zhang J, He J, Lu Y, Lan T Front Endocrinol (Lausanne). 2025; 16:1498207.

PMID: 40017691 PMC: 11864957. DOI: 10.3389/fendo.2025.1498207.

Temporal Trends in the Burden of Diabetes and Its Risk Factors Across the Western Pacific Region Between 1990 and 2044: A Systematic Analysis of the Global Burden of Disease Study 2019.

Liu X, Wu B, Lai Y, Zhang X, Li H, Qu F Diabetes Metab Res Rev. 2025; 41(2):e70036.

PMID: 39983069 PMC: 11845174. DOI: 10.1002/dmrr.70036.

Mechanisms of inflammatory microenvironment formation in cardiometabolic diseases: molecular and cellular perspectives.

Liu M, Chen R, Zheng Z, Xu S, Hou C, Ding Y Front Cardiovasc Med. 2025; 11:1529903.

PMID: 39877020 PMC: 11772298. DOI: 10.3389/fcvm.2024.1529903.

Efficient diagnosis of diabetes mellitus using an improved ensemble method.

Olorunfemi B, Ogunde A, Almogren A, Adeniyi A, Ajagbe S, Bharany S Sci Rep. 2025; 15(1):3235.

PMID: 39863685 PMC: 11762279. DOI: 10.1038/s41598-025-87767-1.

Exploring the causal relationships between type 2 diabetes and neurological disorders using a Mendelian randomization strategy.

Wei Y, Xu S, Wu Z, Zhang M, Bao M, He B Medicine (Baltimore). 2024; 103(46):e40412.

PMID: 39560586 PMC: 11576012. DOI: 10.1097/MD.0000000000040412.

References

Liang R, Feng X, Shi D, Yang M, Yu L, Liu W . The global burden of disease attributable to high fasting plasma glucose in 204 countries and territories, 1990-2019: An updated analysis for the Global Burden of Disease Study 2019. Diabetes Metab Res Rev. 2022; 38(8):e3572. DOI: 10.1002/dmrr.3572. View

Primavera M, Giannini C, Chiarelli F . Prediction and Prevention of Type 1 Diabetes. Front Endocrinol (Lausanne). 2020; 11:248. PMC: 7326081. DOI: 10.3389/fendo.2020.00248. View

Liu J, Bai R, Chai Z, Cooper M, Zimmet P, Zhang L . Low- and middle-income countries demonstrate rapid growth of type 2 diabetes: an analysis based on Global Burden of Disease 1990-2019 data. Diabetologia. 2022; 65(8):1339-1352. PMC: 9118183. DOI: 10.1007/s00125-022-05713-6. View

Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

Tuomilehto J . The emerging global epidemic of type 1 diabetes. Curr Diab Rep. 2013; 13(6):795-804. DOI: 10.1007/s11892-013-0433-5. View

Tachkov K, Zemplenyi A, Kamusheva M, Dimitrova M, Siirtola P, Ponten J . Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries. Front Public Health. 2022; 10:921226. PMC: 9330148. DOI: 10.3389/fpubh.2022.921226. View

. Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM air pollution, 1990-2019: an analysis of data from the Global Burden of Disease Study 2019. Lancet Planet Health. 2022; 6(7):e586-e600. PMC: 9278144. DOI: 10.1016/S2542-5196(22)00122-X. View

Afshin A, Forouzanfar M, Reitsma M, Sur P, Estep K, Lee A . Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017; 377(1):13-27. PMC: 5477817. DOI: 10.1056/NEJMoa1614362. View

Gore A, Chappell V, Fenton S, Flaws J, Nadal A, Prins G . EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr Rev. 2015; 36(6):E1-E150. PMC: 4702494. DOI: 10.1210/er.2015-1010. View

10.

Zhang X, Wang X, Wang M, Hu B, Tang W, Wu Y . The global burden of type 2 diabetes attributable to high body mass index in 204 countries and territories, 1990-2019: An analysis of the Global Burden of Disease Study. Front Public Health. 2022; 10:966093. PMC: 9500174. DOI: 10.3389/fpubh.2022.966093. View

11.

Sattar N, McMurray J, Boren J, Rawshani A, Omerovic E, Berg N . Twenty Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study. Circulation. 2023; 147(25):1872-1886. DOI: 10.1161/CIRCULATIONAHA.122.063374. View

12.

Fiorentino T, Prioletta A, Zuo P, Folli F . Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des. 2013; 19(32):5695-703. DOI: 10.2174/1381612811319320005. View

13.

Geng T, Zhu K, Lu Q, Wan Z, Chen X, Liu L . Healthy lifestyle behaviors, mediating biomarkers, and risk of microvascular complications among individuals with type 2 diabetes: A cohort study. PLoS Med. 2023; 20(1):e1004135. PMC: 9831321. DOI: 10.1371/journal.pmed.1004135. View

14.

Janez A, Battelino T, Klupa T, Kocsis G, Kuricova M, Lalic N . Hybrid Closed-Loop Systems for the Treatment of Type 1 Diabetes: A Collaborative, Expert Group Position Statement for Clinical Use in Central and Eastern Europe. Diabetes Ther. 2021; 12(12):3107-3135. PMC: 8586062. DOI: 10.1007/s13300-021-01160-5. View

15.

Bollyky T, Templin T, Cohen M, Dieleman J . Lower-Income Countries That Face The Most Rapid Shift In Noncommunicable Disease Burden Are Also The Least Prepared. Health Aff (Millwood). 2017; 36(11):1866-1875. PMC: 7705176. DOI: 10.1377/hlthaff.2017.0708. View

16.

Elek P, Biro A . Regional differences in diabetes across Europe - regression and causal forest analyses. Econ Hum Biol. 2020; 40:100948. DOI: 10.1016/j.ehb.2020.100948. View

17.

Fouladi F, Bailey M, Patterson W, Sioda M, Blakley I, Fodor A . Air pollution exposure is associated with the gut microbiome as revealed by shotgun metagenomic sequencing. Environ Int. 2020; 138:105604. PMC: 7181344. DOI: 10.1016/j.envint.2020.105604. View

18.

Miller R, Costacou T, Orchard T . Risk Factor Modeling for Cardiovascular Disease in Type 1 Diabetes in the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study: A Comparison With the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and.... Diabetes. 2018; 68(2):409-419. PMC: 6341302. DOI: 10.2337/db18-0515. View

19.

. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1223-1249. PMC: 7566194. DOI: 10.1016/S0140-6736(20)30752-2. View

20.

Htay T, Soe K, Lopez-Perez A, Doan A, Romagosa M, Aung K . Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. Curr Cardiol Rep. 2019; 21(6):45. DOI: 10.1007/s11886-019-1133-9. View